Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10502120rdf:typepubmed:Citationlld:pubmed
pubmed-article:10502120lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:10502120lifeskim:mentionsumls-concept:C0017668lld:lifeskim
pubmed-article:10502120lifeskim:mentionsumls-concept:C0042874lld:lifeskim
pubmed-article:10502120lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:10502120lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:10502120pubmed:issue8lld:pubmed
pubmed-article:10502120pubmed:dateCreated1999-10-28lld:pubmed
pubmed-article:10502120pubmed:abstractTextExperimental data indicate that excessive production of reactive oxygen molecules contributes to progressive renal injury and that treatment with antioxidants attenuates this damage. Therefore, we investigated whether vitamin E supplementation could ameliorate renal disease and reduce proteinuria in children with a variety of kidney disorders. Vitamin E, 200 IU twice daily, was administered orally to 11 children with focal segmental glomerulosclerosis (FSGS) (group A) and 9 patients with miscellaneous kidney diseases (group B) [Henoch-Schönlein purpura nephritis (n=3), urinary tract anomalies (n=2), non-specific immune complex glomerulonephritis (n=2), IgA nephropathy (n=1), and reflux nephropathy (n=1)]. The duration of vitamin E treatment, when no other therapy was introduced, was 2.9+/-0.4 months. Proteinuria was determined by measuring the protein:creatinine ratio (mg/mg) in an early morning urine specimen. In children with FSGS, administration of vitamin E lowered the protein:creatinine ratio in 10 of 11 patients from 9. 7+/-5.1 to 4.1+/-1.1 (P<0.005). In contrast, among children with miscellaneous renal diseases, vitamin E had no beneficial impact on urinary protein excretion-protein:creatinine ratio 2.5+/-1.0 pre versus 2.4+/-1.2 post antioxidant. Vitamin E supplementation had no effect on glomerular filtration rate, serum albumin, or cholesterol concentration in either group of patients. These findings suggest that reactive oxygen molecules may play a more-prominent role in causing renal injury in patients with FSGS than in other kidney disorders. Antioxidant therapy may be a useful adjunct in the treatment of children with FSGS and proteinuria that is refractory to standard medical management.lld:pubmed
pubmed-article:10502120pubmed:languageenglld:pubmed
pubmed-article:10502120pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10502120pubmed:citationSubsetIMlld:pubmed
pubmed-article:10502120pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10502120pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10502120pubmed:statusMEDLINElld:pubmed
pubmed-article:10502120pubmed:monthOctlld:pubmed
pubmed-article:10502120pubmed:issn0931-041Xlld:pubmed
pubmed-article:10502120pubmed:authorpubmed-author:FrankRRlld:pubmed
pubmed-article:10502120pubmed:authorpubmed-author:GauthierBBlld:pubmed
pubmed-article:10502120pubmed:authorpubmed-author:ValderramaEElld:pubmed
pubmed-article:10502120pubmed:authorpubmed-author:TrachtmanHHlld:pubmed
pubmed-article:10502120pubmed:authorpubmed-author:TahzibMMlld:pubmed
pubmed-article:10502120pubmed:issnTypePrintlld:pubmed
pubmed-article:10502120pubmed:volume13lld:pubmed
pubmed-article:10502120pubmed:ownerNLMlld:pubmed
pubmed-article:10502120pubmed:authorsCompleteYlld:pubmed
pubmed-article:10502120pubmed:pagination649-52lld:pubmed
pubmed-article:10502120pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10502120pubmed:meshHeadingpubmed-meshheading:10502120...lld:pubmed
pubmed-article:10502120pubmed:meshHeadingpubmed-meshheading:10502120...lld:pubmed
pubmed-article:10502120pubmed:meshHeadingpubmed-meshheading:10502120...lld:pubmed
pubmed-article:10502120pubmed:meshHeadingpubmed-meshheading:10502120...lld:pubmed
pubmed-article:10502120pubmed:meshHeadingpubmed-meshheading:10502120...lld:pubmed
pubmed-article:10502120pubmed:meshHeadingpubmed-meshheading:10502120...lld:pubmed
pubmed-article:10502120pubmed:meshHeadingpubmed-meshheading:10502120...lld:pubmed
pubmed-article:10502120pubmed:meshHeadingpubmed-meshheading:10502120...lld:pubmed
pubmed-article:10502120pubmed:meshHeadingpubmed-meshheading:10502120...lld:pubmed
pubmed-article:10502120pubmed:meshHeadingpubmed-meshheading:10502120...lld:pubmed
pubmed-article:10502120pubmed:year1999lld:pubmed
pubmed-article:10502120pubmed:articleTitleVitamin E treatment of focal segmental glomerulosclerosis: results of an open-label study.lld:pubmed
pubmed-article:10502120pubmed:affiliationDivision of Nephrology, Schneider Children's Hospital of Long Island Jewish Medical Center, Long Island Campus of the Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA.lld:pubmed
pubmed-article:10502120pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10502120lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10502120lld:pubmed